Annexon Inc is a biopharmaceutical company focused on developing innovative therapies to address neurodegenerative diseases and autoimmune disorders. Utilizing its expertise in complement and neuroinflammation biology, the company aims to discover and advance novel treatments that can effectively restore healthy function in the nervous system and beyond. Annexon's approach is centered on targeting the underlying mechanisms of disease, thereby offering potential for improved outcomes for patients suffering from various conditions, including Alzheimer’s disease and other debilitating disorders. Through its commitment to scientific innovation, Annexon seeks to make a meaningful impact on patient health and enhance the quality of life for those affected by these challenging diseases. Read More
Annexon (NASDAQ:ANNX) said it expanded its pivotal ARCHER II trial of vonaprument in geographic atrophy, adding an independent 24-month dual primary endpoint alongside the study’s existing 15-month primary endpoint. The company said it remains confident in a planned fourth-quarter assessment of the
Rapid, Positive Clinical Outcomes in GBS FORWARD Study Reinforce Consistency and Reproducibility of Tanruprubart Treatment Effect Demonstrated in Phase 3 and Real-World Evidence Studies; BLA Submission Expected in Q4 2026
BRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced the addition of a Month 24 dual primary endpoint to complement the current Month 15 primary endpoint in its Phase 3 ARCHER II trial, and launch of an open-label extension (OLE) study of vonaprument for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA). With a dual primary endpoint strategy, ARCHER II can achieve success in protecting against vision loss at either Month 15 or 24, which are independent efficacy timepoints.
Early Outcomes Reinforce the Consistency and Reproducibility of Tanruprubart Treatment Effect Previously Demonstrated in Phase 3 and Real-World Evidence Studies
BRISBANE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on July 12, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).
BRISBANE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced an oral presentation on the neuroprotective effect of vonaprument at the American Society of Retina Specialists (ASRS) 44th Annual Scientific Meeting being held July 15–18, 2026 in Montréal, Québec, Canada.
BRISBANE, Calif., June 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on June 13, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).
Annexon (NASDAQ:ANNX) executives used a Goldman Sachs Healthcare Conference session to outline the company’s upcoming clinical and regulatory catalysts, led by pivotal Phase III data expected in the fourth quarter for vonaprument in geographic atrophy, a form of advanced dry age-related macular dege
Annexon (NASDAQ:ANNX) executives outlined a series of expected clinical and regulatory updates across the company’s complement-focused pipeline during a session at the Jefferies Conference, highlighting programs in geographic atrophy, Guillain-Barré syndrome and cold agglutinin disease.
Douglas Lov
BRISBANE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following June investor conferences:
BRISBANE, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to three new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on May 11, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).
Annexon (NASDAQ:ANNX) President and CEO Doug Love outlined the company’s late-stage pipeline and regulatory plans during a presentation at the Bank of America Healthcare Conference, highlighting upcoming data in geographic atrophy and regulatory filings for Guillain-Barré syndrome.
Love described A
Topline Pivotal Phase 3 Data for Vonaprument for the Treatment of Geographic Atrophy (GA) Expected Q4 2026, with Potential to Redefine Vision Preservation in GA
BRISBANE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., President and Chief Executive Officer, will present at the Bank of America Securities Health Care Conference 2026 on Wednesday, May 13, 2026 at 11:20 a.m. PT.
In a move that has sent shockwaves through the biotechnology sector, Apellis Pharmaceuticals (Nasdaq: APLS) witnessed an extraordinary 135.7% surge in its share price on March 31, 2026. The massive technical breakout followed the announcement that Biogen (Nasdaq: BIIB) has entered into a definitive agreement to acquire the leader
ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA
BRISBANE, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on March 12, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).
BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president and chief executive officer, will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026 at 9:50 a.m. ET.
BRISBANE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it will host an in-person and virtual key opinion leader (KOL) event in New York on Wednesday, March 18, 2026, with presentations at 2:00 PM ET and a reception at 4:00 PM ET. To register, click here.
BRISBANE, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on January 9, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).
Tanruprubart MAA Filed with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barré Syndrome (GBS); BLA Submission with U.S./European Data Planned in 2026
